Clinical trials: Fasting Hypoglycemia
Type II Diabetes Mellitus
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady…
- Trial name
- NCT07340320
- Testing
- CX11
- Where
- 48 sites in United States, Poland
- Volunteers
- 240 people
- Sponsor
- Corxel Pharmaceuticals
Type 2 Diabetes Mellitus (T2DM)
Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)
This study will examine whether the incidence of hypoglycemia in patients fasting for Ramadan is lower when treated with sitagliptin as compared to sulfonylurea treatment.
- Trial name
- NCT01131182
- Testing
- Sitagliptin phosphate, Comparator: Sulfonylurea, Metformin
- Volunteers
- 1,147 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan
To evaluate vildagliptin as compared to gliclazide, given in combination with metformin in Muslim patients with type 2 diabetes fasting during Ramadan.
- Trial name
- STEADFAST (NCT01758380)
- Testing
- Vildagliptin, Gliclazide, Metformin
- Where
- 68 sites in Denmark, Egypt and 14 more
- Volunteers
- 557 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)
This is a study comparing the incidence of hypoglycemia while using sitagliptin treatment versus sulfonylurea (SU) treatment in participants with type 2 diabetes mellitus (T2DM) who regularly take an SU drug, and choose to fast…
- Trial name
- NCT01340768
- Testing
- Sitagliptin, Sulfonylurea, Metformin
- Volunteers
- 870 people
- Sponsor
- Merck Sharp & Dohme LLC
Pharmacological Action
Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients
Sitagliptin, through its effects on sensitizing alpha-cell sensitivity to glucose, can initiate counter-regulatory glucagon responses at higher glycemic thresholds, thus reducing the number of clinically apparent hypoglycemic…
- Trial name
- NCT03359590
- Testing
- Sitagliptin 100 mg
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH